|1.||Mikhaleva, I I: 12 articles (01/2014 - 06/2001)|
|2.||Bondarenko, T I: 8 articles (01/2014 - 06/2001)|
|3.||Stanojlović, Olivera: 5 articles (11/2007 - 02/2004)|
|4.||Prudchenko, I A: 4 articles (01/2013 - 04/2006)|
|5.||Sudakov, K V: 4 articles (11/2008 - 01/2003)|
|6.||Koplik, E V: 4 articles (11/2008 - 01/2003)|
|7.||Zivanović, Dragana: 4 articles (09/2007 - 02/2004)|
|8.||Kutilin, D S: 3 articles (01/2014 - 01/2014)|
|9.||Maĭboroda, E A: 3 articles (01/2013 - 01/2011)|
|10.||Susić, Veselinka: 3 articles (11/2007 - 01/2006)|
01/01/2006 - "DSIP or VPA alone expressed no significant effect on the latency duration, but their combination significantly prolonged latency to seizure during 6 h after injection, while inducing no significant motor impairment. "
02/01/1995 - "Authors suppose that changes of DSIP structure lead to changes of effects expression on locomotor and seizure activity in conditions of their administration into substantia nigra reticulata. "
02/01/1995 - "[The effect of the intranigral use of the delta sleep-inducing peptide and its analogs on the motor and seizure activities of rats]."
05/01/1992 - "[The effect of the delta sleep-inducing peptide on seizure activity]."
02/01/1989 - "Anticonvulsant action of DSIP was evident under the condition of the mild severity seizures development. "
|2.||Sleep Initiation and Maintenance Disorders (Insomnia)
01/01/1983 - "In preliminary clinical trials, DSIP has shown promise for the treatment of insomnia and the opiate and alcohol withdrawal syndromes.(ABSTRACT TRUNCATED AT 250 WORDS)"
01/01/1992 - "As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit."
01/01/1987 - "Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia."
01/01/1984 - "The results are discussed as to the mode of action of DSIP and its possible therapeutic use in insomnia."
01/01/1984 - "DSIP in insomnia."
|3.||Brain Ischemia (Cerebral Ischemia)
07/01/1998 - "Effects of delta-sleep-inducing peptide in cerebral ischemia in rats."
07/01/1998 - "Experimental studies were carried out to investigate the neuroprotective effects of delta sleep-inducing peptide in animals with cerebral ischemia induced by bilateral compression of both carotid arteries, and to compare the efficacy of this peptide with that of MK-801. "
11/01/2008 - "The aims of the present work were to perform a comparative study of the effects of delta sleep-inducing peptide and Deltaran on neurons in emotiogenic brain structures and to address the question of whether it is possible to prevent or decrease the negative influences of stress loads on the severity of subsequent cerebral ischemia in rats, using glycine with delta sleep-inducing peptide combined in the neuroprotective formulation Deltaran. "
01/01/2007 - "Another goal was to analyze the possibility to prevent negative effects of emotional stress on brain ischemia using, along with deltaran, glycine and a delta-sleep inducing peptide. "
|4.||Body Weight (Weight, Body)
01/01/1992 - "In the afternoon before the 3rd, 4th and 5th night, half of the patients received intravenously 25 nmol/kg body weight DSIP, and half of the patients a glucose solution (placebo). "
03/01/1985 - "The normalizing effect on the level of extraerythrocyte hemoglobin and activity of glucose-6-phosphatedehydrogenase in low ambient temperature occurs at the dose of DSIP 12 micrograms/100 g body weight. "
08/01/1984 - "It was reported that DSIP reversed the increase in temperature of rats injected at room temperature with 15 mg d-amphetamine per kg body weight. "
01/01/2014 - "It is shown that exogenous delta-sleep inducing peptide increases glutathione antioxidant system level in rat tissues at different stages of ontogenesis, by subcutaneous injection to rats 2-24 months postnatal development in a dose of 100 mg/kg animal body weight by courses of 5 consecutive days per month, and this effect is especially marked in non-renewable postmitotic tissues."
01/01/2012 - "The authors show that exogenous delta-sleep inducing peptide (DSIP) injected subcutaneously to the rats in the age of 2-24 months of postnatal development in a dose of 100 mg/kg of animal body weight in courses for 5 consecutive days every month, has a hepatoprotective effect. "
04/01/1995 - "Preliminary injection of DSIP prevents disturbances in the permeability of lysosomal membranes under long-term (24 hours) hypokinesia."
04/01/1995 - "[Proteolytic processes in the rat brain and serum in hypokinesia and the adaptive effect of delta-sleep inducing peptide]."
01/01/1996 - "[The neuromediator mechanism of the additive action of the delta sleep-inducing peptide in experimental audiogenic epilepsy caused by hypokinesia]."
09/01/1992 - "Injection DSIP induces a decrease A/B of cathepsin D to the control level under 1-h hypokinesia condition and normalizes the neutral proteolytic activity under 6-h hypokinesia condition."
09/01/1992 - "[Influence of delta-sleep-inducing peptide on the activity of proteolytic enzymes in the rat brain under hypokinesia]."
|2.||Delta Sleep-Inducing Peptide
|4.||Valproic Acid (Valproate, Semisodium)
|5.||Dizocilpine Maleate (Dizocilpine)
|6.||beta-Endorphin (Endorphin, beta)
|4.||Intensive Care (Surgical Intensive Care)